The aim was to determine whether serum prorenin levels affect the development of diabetic retinopathy (DR) in type 2 diabetes. Baseline serum prorenin levels were measured in 196 patients (85 males, 111 females) with type 2 diabetes without DR using the antibody-activating direct prorenin assay. The fundi were checked regularly. The participants were divided into two groups based on the serum prorenin levels (high and low). We used Kaplan—Meyer analysis to detect differences in the development of DR between the two groups within the same gender. Kaplan—Meyer analysis showed that males with a high serum prorenin level tended to develop DR earlier and more frequently than males with a low prorenin level ( p = 0.004 by the log rank test). However, there was no difference in the development of DR between high and low groups in females (p = 0.58). Serum prorenin levels in males with type 2 diabetes could be a new prognostic indicator of the development of DR.
Chaturvedi N. , Sjolie AK, Stephenson JM et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet1998; 351: 28-31.
2.
Chaturvedi N. , Porta M., Klein R. et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet2008; 372: 1394-1402.
3.
Sjolie AK, Klein R., Porta M. et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial . Lancet2008; 372: 1385-1393.
4.
Luetscher JA , Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M.Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med1985; 312: 1412-1417.
5.
Satofuka S., Ichihara A., Nagai N. et al. (Pro)renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. Diabetes2009; 58: 1625-1633.
6.
Suzuki F., Hayakawa M., Nakagawa T. et al. Human prorenin has ‘gate and handle’ regions for its non-proteolytic activation. J Biol Chem2003 ; 278: 22217-22222.
7.
Ichihara A., Hayashi M., Kaneshiro Y. et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the ‘handle’ region for nonproteolytic activation of prorenin . J Clin Invest2004; 114: 1128-1135.
8.
Ichihara A., Kaneshiro Y., Suzuki F.Prorenin receptor blockers: effects on cardiovascular complications of diabetes and hypertension. Expert Opin Investig Drugs2006; 15: 1137-1139.
9.
Funke-Kaiser H., Zollmann FS, Schefe JH, Unger T.Signal transduction of the (pro)renin receptor as a novel therapeutic target for preventing end-organ damage. Hypertens Res. 2010; 33(2): 98-104.
10.
Yokota H., Mori F., Kai K. et al. Serum prorenin levels and diabetic retinopathy in type 2 diabetes: new method to measure serum level of prorenin using antibody activating direct kinetic assay. Br J Ophthalmol2005; 89: 871-873.
11.
Derkx FH, Alberda AT, de Jong FH, Zeilmaker FH, Makovitz JW, Schalekamp MASource of plasma prorenin in early and late pregnancy: observations in a patient with primary ovarian failure. J Clin Endocrinol Metab1987; 65: 349-354.
12.
Kawazu S., Minagawa S., Yazawa M. et al. Sex difference and possible relationship to microvascular complications of serum prorenin levels in type 2 diabetic patients, measured by a novel antibody-activating direct enzyme kinetic assay. J Diabetes Complications2004; 18: 275-281.
13.
Kordonouri O. , Wladimirowa A., Danne T.High total serum renin concentrations are associated with the development of background retinopathy in adolescents with type 1 diabetes. Diabetes Care2000; 23: 1025-1026.
14.
Chen YF, Naftilan AJ, Oparil S.Androgen-dependent angiotensinogen and renin messenger RNA expression in hypertensive rats. Hypertension1992; 19: 456-463.
15.
Otani A., Takagi H., Suzuma K., Honda Y.Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res1998; 82: 619-628.
16.
Rojas M., Zhang W., Lee D. et al. Role of IL-6 in angiotensin II-induced retinal vascular inflammation . Invest Ophthalmol Vis Sci2010; 51(3): 1709-1718.
17.
Zhang JZ, Xi X., Gao L., Kern TSCaptopril inhibits capillary degeneration in the early stages of diabetic retinopathy. Curr Eye Res2007; 32: 883-889.
18.
Nagisa Y., Shintani A., Nakagawa S.The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats. Diabetologia2001 ; 44: 883-888.
19.
Mori F., Hikichi T., Nagaoka T., Takahashi J., Kitaya N., Yoshida A.Inhibitory effect of losartan, an AT1 angiotensin II receptor antagonist, on increased leucocyte entrapment in retinal microcirculation of diabetic rats. Br J Ophthalmol2002; 86: 1172-1174.
20.
Tadesse M., Yan Y., Yossuck P., Higgins RDCaptopril improves retinal neovascularization via endothelin-1. Invest Ophthalmol Vis Sci2001; 42: 1867-1872.
21.
Moravski CJ , Kelly DJ, Cooper ME et al. Retinal neovascularization is prevented by blockade of the renin- angiotensin system. Hypertension2000; 36: 1099-1104.
